That study newly revealed the therapeutic capability of rigosertib in HCC by inhibition via simultaneous inhibition of PLK1 activation and major RAS-pathways, unveiling a novel therapeutic method for HCC [233]. Here, PLK1 is linked to hepatocellular carcinoma.